ArticleCureus2025
Psychiatric Manifestations of Delta-8-Tetrahydrocannabinol (Δ8-THC) Use Among Patients With Preexisting Psychiatric Disorders: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delta-8-tetrahydrocannabinol (Δ8-THC) products, made from hemp-derived cannabidiol, have become more widely available since changes in legislation allowed hemp to be excluded from controlled substances. These products are often perceived as a safe, legal, and accessible alternative to marijuana or delta-9-tetrahydrocannabinol. However, scientific research on their effects remains limited. There have been reports of psychiatric symptoms associated with Δ8-THC use, although the literature is not yet comprehensive. In this report, we present three cases of patients with distinct preexisting psychiatric disorders who developed various psychiatric manifestations, including psychosis, after using Δ8-THC products. All three individuals had purchased these products legally, believing them to be safe and effective for managing their symptoms. However, their use ultimately led to psychiatric symptoms severe enough to require hospitalization. This case series highlights the need for greater awareness of the potential psychiatric effects of Δ8-THC, particularly among individuals with preexisting mental health conditions, and underscores the critical gap in research on these products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.